Related Experiment Video
Updated: Sep 9, 2025
05:19
Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors
Published on: March 29, 2019
10.4K
Prognostic Factors of Long-Term Survival in Non-Muscle-Invasive Bladder Cancer: An 18-Year Retrospective Study from
Chirurgia (Bucharest, Romania : 1990)
|September 4, 2025
Summary
Older age and multiple tumors impact non-muscle-invasive bladder cancer (NMIBC) survival. Risk scores predict outcomes, but BCG therapy
Area of Science:
- Urology
- Oncology
- Public Health
Background:
- Non-muscle-invasive bladder cancer (NMIBC) is a common and heterogeneous disease.
- Bacillus Calmette-Guérin (BCG) is the standard treatment for intermediate- and high-risk NMIBC.
- BCG effectiveness can be limited by access, tolerance, resistance, and healthcare disruptions.
Purpose of the Study:
- To identify prognostic factors for survival in NMIBC patients.
- To assess the potential influence of the COVID-19 pandemic on treatment outcomes.
- To evaluate the utility of EORTC risk scores in a real-world setting.
Main Methods:
- Retrospective analysis of 100 NMIBC patients diagnosed between 2006-2008, with follow-up until 2024.
- Prognostic analysis included clinical variables and EORTC RecScore and ProgScore.
- Scores were analyzed as continuous variables without predefined cut-offs.
Main Results:
- Age over 70 and tumor multiplicity were significantly associated with increased mortality.
- RecScore significantly correlated with relapse risk (p=0.0464).
- BCG therapy showed a marginal protective effect but did not significantly influence survival.
Conclusions:
- Personalized, risk-based strategies are crucial for NMIBC management.
- Real-world data integration is vital, especially amidst systemic disruptions like the COVID-19 pandemic.
- Further research is needed to fully understand the impact of external factors on NMIBC treatment outcomes.
